Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutics, Inc. - Common Stock
(NQ:
HALO
)
77.18
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years
↗
July 07, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
↗
June 28, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth investing.
Via
Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
↗
June 25, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers a rare mix of strong growth, profitability, and financial health at an attractive valuation, making it a standout in the biotech sector.
Via
Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Strong Growth Stock with Technical Breakout Potential
↗
June 17, 2025
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows strong growth fundamentals and a potential technical breakout, making it a stock to watch in the biotech sector.
Via
Chartmill
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today
↗
June 12, 2025
Via
Benzinga
What's Driving the Market Sentiment Around Halozyme Therapeutics?
↗
May 28, 2025
Via
Benzinga
Price Over Earnings Overview: Halozyme Therapeutics
↗
May 28, 2025
Via
Benzinga
Earnings Scheduled For May 6, 2025
↗
May 06, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
↗
June 07, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth...
Via
Chartmill
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
↗
June 04, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
↗
June 03, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong profitability, financial health, and growth at an attractive valuation, making it a potential value opportunity in biotech.
Via
Chartmill
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
↗
May 24, 2025
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at what's drivin the interest.
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
↗
May 17, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth...
Via
Chartmill
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday
↗
May 16, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
May 13, 2025
Via
Benzinga
Crude Oil Gains 3%; US Inflation Eases In April
↗
May 13, 2025
Via
Benzinga
Topics
Economy
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
May 13, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
↗
May 13, 2025
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via
Chartmill
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
↗
May 13, 2025
It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected.
Via
Investor's Business Daily
Topics
Economy
Government
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – An Undervalued Biotech Stock Worth Watching
↗
May 13, 2025
HALOZYME THERAPEUTICS (NASDAQ:HALO) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a compelling pick for value investors.
Via
Chartmill
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years
↗
May 09, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
May 07, 2025
Via
Benzinga
Insights into Halozyme Therapeutics's Upcoming Earnings
↗
May 05, 2025
Via
Benzinga
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable.
↗
April 26, 2025
HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
Via
Chartmill
Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings)
↗
April 25, 2025
Via
Benzinga
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief
↗
April 24, 2025
Halozyme said that it believes the subcutaneous formulation of Merck's cancer medicine Keytruda infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE...
Via
Stocktwits
Topics
Intellectual Property
Lawsuit
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
↗
April 22, 2025
Via
Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.
↗
April 18, 2025
Based on a technical and fundamental analysis of NASDAQ:HALO we conclude: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
↗
April 11, 2025
FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options.
Via
Benzinga
Peering Into Halozyme Therapeutics's Recent Short Interest
↗
April 11, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
